Library Header Image
LSE Research Online LSE Library Services

Economic evaluation of anti-epileptic medicines for autistic children with epilepsy

Tinelli, Michela ORCID: 0000-0002-8816-4389, Roddy, Áine, Knapp, Martin ORCID: 0000-0003-1427-0215, Arango, Celso, Mendez, Maria Andreina, Henderson, Catherine, Murphy, Declan, Canitano, Roberto, Oakley, Bethany and Quoidbach, Vinciane (2023) Economic evaluation of anti-epileptic medicines for autistic children with epilepsy. Journal of Autism and Developmental Disorders. ISSN 1573-3432

[img] Text (Tinelli_economic-evaluation-of-anti-epileptic-medicines--published) - Published Version
Available under License Creative Commons Attribution.

Download (1MB)

Identification Number: 10.1007/s10803-023-05941-8


We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children’s families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For England and Spain, oxcarbazepine is the most cost-effective treatment when taken as additional treatment for those children whose response to monotherapy is suboptimal. In Ireland and Italy, gabapentin is the most cost-effective option. Our additional scenario analysis presents the aggregate cost to families with autistic children who are being treated for epilepsy: this cost is considerably higher than healthcare provider expenditure.

Item Type: Article
Official URL:
Additional Information: © 2023 The Authors
Divisions: Personal Social Services Research Unit
Health Policy
Subjects: R Medicine > RJ Pediatrics > RJ101 Child Health. Child health services
R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine
R Medicine > RM Therapeutics. Pharmacology
Date Deposited: 20 Feb 2023 10:18
Last Modified: 22 Jul 2024 00:09

Actions (login required)

View Item View Item


Downloads per month over past year

View more statistics